EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study

Background Electronic cigarettes (e-cigarettes) are becoming increasingly popular with smokers worldwide. Users report buying them to help quit smoking, to reduce cigarette consumption, to relieve tobacco withdrawal symptoms, and to continue having a ‘smoking’ experience, but with reduced health risks. Research on e-cigarettes is urgently needed in order to ensure that the decisions of regulators, healthcare providers and consumers are based on science. Methods ECLAT is a prospective 12-month randomized, controlled trial that evaluates smoking reduction/abstinence in 300 smokers not intending to quit experimenting two different nicotine strengths of a popular e-cigarette model (‘Categoria’; Arbi Group Srl, Italy) compared to its non-nicotine choice. GroupA (n = 100) received 7.2 mg nicotine cartridges for 12 weeks; GroupB (n = 100), a 6-week 7.2 mg nicotine cartridges followed by a further 6-week 5.4 mg nicotine cartridges; GroupC (n = 100) received no-nicotine cartridges for 12 weeks. The study consisted of nine visits during which cig/day use and exhaled carbon monoxide (eCO) levels were measured. Smoking reduction and abstinence rates were calculated. Adverse events and product preferences were also reviewed. Results Declines in cig/day use and eCO levels were observed at each study visits in all three study groups (p<0.001 vs baseline), with no consistent differences among study groups. Smoking reduction was documented in 22.3% and 10.3% at week-12 and week-52 respectively. Complete abstinence from tobacco smoking was documented in 10.7% and 8.7% at week-12 and week-52 respectively. A substantial decrease in adverse events from baseline was observed and withdrawal symptoms were infrequently reported during the study. Participants’ perception and acceptance of the product under investigation was satisfactory. Conclusion In smokers not intending to quit, the use of e-cigarettes, with or without nicotine, decreased cigarette consumption and elicited enduring tobacco abstinence without causing significant side effects. Trial Registration ClinicalTrials.gov NCT01164072 NCT01164072

[1]  Leon Kosmider,et al.  Nicotine levels in electronic cigarettes. , 2013, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[2]  R. Polosa,et al.  Handling relapse in smoking cessation: strategies and recommendations , 2013, Internal and Emergency Medicine.

[3]  L. Dawkins,et al.  The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. , 2012, Addictive behaviors.

[4]  P. Aveyard,et al.  Weight gain in smokers after quitting cigarettes: meta-analysis , 2012, BMJ : British Medical Journal.

[5]  Pasquale Caponnetto,et al.  The emerging phenomenon of electronic cigarettes , 2012, Expert review of respiratory medicine.

[6]  K. Fagerström Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[7]  R. Polosa,et al.  Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series , 2011, Journal of medical case reports.

[8]  J. Etter,et al.  Saliva cotinine levels in users of electronic cigarettes , 2011, European Respiratory Journal.

[9]  J. Etter,et al.  Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. , 2011, Addiction.

[10]  Pasquale Caponnetto,et al.  Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study , 2011, BMC public health.

[11]  R. Polosa,et al.  Smoking Cessation with E-Cigarettes in Smokers with a Documented History of Depression and Recurring Relapses , 2011 .

[12]  R. Polosa,et al.  Effect of a nicotine-free inhalator as part of a smoking-cessation programme , 2011, European Respiratory Journal.

[13]  M. Siegel,et al.  Electronic cigarettes as a smoking-cessation: tool results from an online survey. , 2011, American journal of preventive medicine.

[14]  Chris Bullen,et al.  Electronic nicotine delivery systems: a research agenda , 2011, Tobacco Control.

[15]  T. Nakao,et al.  Safety Assessment of Electronic Cigarettes in Smokers , 2011 .

[16]  M. Siegel,et al.  Electronic cigarettes as a harm reduction strategy for tobacco control: A step forward or a repeat of past mistakes? , 2011, Journal of public health policy.

[17]  T. Eissenberg,et al.  A Clinical Laboratory Model for Evaluating the Acute Effects of Electronic “Cigarettes”: Nicotine Delivery Profile and Cardiovascular and Subjective Effects , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[18]  R. Polosa,et al.  Therapeutic advances in the treatment of nicotine addiction: present and future , 2010, Therapeutic advances in chronic disease.

[19]  Jean-François Etter,et al.  Electronic cigarettes: a survey of users , 2010, BMC public health.

[20]  H McRobbie,et al.  Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial , 2010, Tobacco Control.

[21]  M. Fiore,et al.  Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. , 2009, Archives of internal medicine.

[22]  Tobacco Use and Dependence Guideline Panel Treating Tobacco Use and Dependence: 2008 Update , 2008 .

[23]  J. Hughes,et al.  Effects of abstinence from tobacco: valid symptoms and time course. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[24]  R. Anziano,et al.  Long-term fatty fish consumption and renal cell carcinoma incidence in women. , 2006, JAMA.

[25]  Å. Westin,et al.  Developmental history of the Glover-Nilsson smoking behavioral questionnaire. , 2005, American journal of health behavior.

[26]  Karl Fagerstrom,et al.  Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire , 1989, Journal of Behavioral Medicine.

[27]  G. Burci World Health Organization (WHO): Framework Convention on Tobacco Control* , 2003, International Legal Materials.

[28]  Raydel Valdés Salgado [The Framework Convention on Tobacco Control]. , 2003, Salud publica de Mexico.

[29]  M. Fiore,et al.  Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. , 2002, Chest.

[30]  M. Goolsby,et al.  Treating Tobacco Use and Dependence , 2008, Pediatrics.

[31]  K. Fagerström,et al.  Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit , 2000, Tobacco control.

[32]  Å. Westin,et al.  Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety , 2000, BMJ : British Medical Journal.

[33]  K. Carroll,et al.  Enhancing retention in clinical trials of psychosocial treatments: practical strategies. , 1997, NIDA research monograph.

[34]  J. Samet Health benefits of smoking cessation. , 1991, Clinics in chest medicine.

[35]  R. Mulcahy The health benefits of smoking cessation. , 1990, Irish medical journal.

[36]  D. Hatsukami,et al.  Effects of Abstinence from Tobacco , 1990 .

[37]  A. Beck,et al.  An inventory for measuring clinical anxiety: psychometric properties. , 1988, Journal of consulting and clinical psychology.

[38]  P. Jacob,et al.  Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. , 1988, American journal of public health.

[39]  N. Benowitz,et al.  Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. , 1981, Journal of chromatography.